SELLAS Life Sciences Group, Inc. 8-K

What Happened

• SELLAS Life Sciences Group, Inc. (SLS) filed an 8‑K (Item 8.01) reporting it had $107.1 million in cash and cash equivalents as of March 31, 2026. Subsequent to that date, in April and May 2026 the company received approximately $28.7 million in proceeds from the exercise of common stock warrants. As of June 2, 2026, SELLAS had 196,632,574 shares of common stock outstanding.

Key Details

• $107.1 million: cash and cash equivalents as of March 31, 2026.
• ~$28.7 million: proceeds from warrant exercises received in April–May 2026.
• 196,632,574: shares of common stock outstanding as of June 2, 2026.
• Disclosure filed under Item 8.01 (Other Events) of Form 8‑K.

Why It Matters

• These items affect the company’s liquidity and capital structure: the reported cash balance plus recent warrant proceeds increase available funds for operations and development. The number of shares outstanding reflects potential dilution from exercised warrants and is important for share‑count based metrics (EPS, market cap). Investors should note the timing and amount of capital inflows but consult upcoming SEC filings (e.g., quarterly results) for more comprehensive financial context.